Pfiz­er, NEA back Cy­dan II's plans to launch a fresh slate of biotech star­tups fo­cused on rare ge­net­ic dis­eases

Six months ago the biotech start­up Vtesse grabbed a $200 mil­lion up­front pay­out for their buy­out deal with Su­cam­po, pro­vid­ing a nice en­dorse­ment for the Cam­bridge, MA-based Cy­dan group that spawned the com­pa­ny.

Now the ex­ecs at Cy­dan say their first ef­fort at spin­ning out ear­ly-stage biotechs fo­cused on ex­tra­or­di­nar­i­ly rare and large­ly over­looked dis­eases is done.

It’s time for Cy­dan II, and the small op­er­a­tion — with sev­en staffers now — has just raised a fresh $34 mil­lion to make it hap­pen. That fig­ure tops the $26 mil­lion Cy­dan start­ed out with in 2013.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER